Reply by Authors

enthalten in: The Journal of urology | 2020

von Almassi, N. | Cha, E. | Vertosick, E. | +12

Reply to Jianhui Du, Yueguang Liu, and Weigang Yan's Letter to the Editor re : Gregory T. Chesnut, Emily A. Vertosick, Nicole Benfante, et al. Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.009

enthalten in: European urology | 2020

von Chesnut, G. | Vertosick, E. | Ehdaie, B.

Reply by Authors

enthalten in: The Journal of urology | 2020

von Vertosick, E. | Häggström, C. | Sjoberg, D. | +5

Reply to Williamson S.R. What is the malignant potential of clear cell papillary renal cell carcinoma? Urol Oncol 2016; 34 : 420

enthalten in: Urologic oncology | 2016

von Nguyen, D. | Hakimi, A. | Vertosick, E. | +1

Histological subtype of renal cell carcinoma significantly affects survival in the era of partial nephrectomy

enthalten in: Urologic oncology | 2016

von Nguyen, D. | Vertosick, E. | Corradi, R. | +5

Re : Alberto Briganti, Thomas Wiegel, Steven Joniau, et al. early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis. Eur Urol 2012;62:472-87: statistical concerns with Briganti radiotherapy analysis

enthalten in: European urology | 2013

von Vertosick, E. | Vickers, A.